1 Name#
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination (No. 9) 2026.
This instrument may also be cited as PB 122 of 2026.
2Commencement#
(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
|---|---|---|
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2026 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4 Schedules#
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 – Amendments
National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)
Omit
| Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | 100 | 4.85 | 6.98 |
| Tablet 200 mg | Oral | Tegretol 200 | 100 | 8.10 | 10.24 |
Insert
| Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | 100 | 6.21 | 6.98 |
Omit
| Cefuroxime | Tablet 250 mg (as axetil) | Oral | Zinnat | 20 | 5.27 | 11.16 |
Insert
| Cefuroxime | Tablet 250 mg (as axetil) | Oral | Zinnat | 20 | 4.31 | 9.13 |
Omit
| Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | Oral | Pristiq | 28 | 6.45 | 10.64 |
| Tablet (extended release) 100 mg (as succinate) | Oral | Pristiq | 28 | 7.92 | 12.11 |
Insert
| Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | Oral | Pristiq | 28 | 6.45 | 10.64 |
| Tablet (extended release) 100 mg (as succinate) | Oral | Pristiq | 28 | 7.02 | 10.73 |
Omit
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | 1 | 7.93 | 8.68 |
Insert
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | 1 | 8.23 | 8.68 |
Omit
| Felodipine | Tablet 5 mg (extended release) | Oral | Plendil ER | 30 | 3.75 | 7.36 |
| Tablet 10 mg (extended release) | Oral | Plendil ER | 30 | 6.79 | 10.28 |
Insert
| Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 30 | 3.11 | 6.80 |
| Tablet 5 mg (extended release) | Oral | Plendil ER | 30 | 3.75 | 7.36 | |
| Tablet 10 mg (extended release) | Oral | Plendil ER | 30 | 6.79 | 10.28 |
Omit
| Indometacin | Capsule 25 mg | Oral | Indocid | 50 | 3.10 | 5.44 |
Insert
| Indometacin | Capsule 25 mg | Oral | Indocid | 50 | 4.53 | 5.44 |
Omit
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 8.03 | 9.07 |
| Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 8.17 | 9.22 | |
| Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 8.32 | 9.36 | |
| Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 9.76 | 10.80 |
Insert
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 7.12 | 8.04 |
| Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 7.24 | 8.17 | |
| Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 7.38 | 8.30 | |
| Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 8.65 | 9.57 |
Omit
| Olanzapine | Tablet 2.5 mg | Oral | Zyprexa | 28 | 3.08 | 10.53 |
| Tablet 5 mg | Oral | Zyprexa | 28 | 4.00 | 13.56 | |
| Tablet 7.5 mg | Oral | Zyprexa | 28 | 4.76 | 9.34 | |
| Tablet 10 mg | Oral | Zyprexa | 28 | 6.34 | 10.92 | |
| Wafer 5 mg | Oral | Zyprexa Zydis | 28 | 4.00 | 13.56 | |
| Wafer 10 mg | Oral | Zyprexa Zydis | 28 | 6.34 | 15.60 | |
| Wafer 15 mg | Oral | Zyprexa Zydis | 28 | 9.52 | 20.36 | |
| Wafer 20 mg | Oral | Zyprexa Zydis | 28 | 12.69 | 23.52 |
Insert
| Olanzapine | Tablet 2.5 mg | Oral | Zyprexa | 28 | 3.08 | 10.53 |
| Tablet 5 mg | Oral | Zyprexa | 28 | 4.00 | 13.56 | |
| Tablet 7.5 mg | Oral | Zyprexa | 28 | 4.21 | 8.26 | |
| Tablet 10 mg | Oral | Zyprexa | 28 | 5.61 | 9.66 | |
| Wafer 5 mg | Oral | Zyprexa Zydis | 28 | 4.00 | 13.56 | |
| Wafer 10 mg | Oral | Zyprexa Zydis | 28 | 6.34 | 15.60 | |
| Wafer 15 mg | Oral | Zyprexa Zydis | 28 | 9.52 | 20.36 | |
| Wafer 20 mg | Oral | Zyprexa Zydis | 28 | 12.69 | 23.52 |
Omit
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 20/5 | 30 | 3.62 | 7.34 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 40/5 | 30 | 5.18 | 8.90 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | Sevikar 40/10 | 30 | 5.56 | 9.28 |
Insert
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 20/5 | 30 | 3.62 | 7.34 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 40/5 | 30 | 4.50 | 7.73 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | Sevikar 40/10 | 30 | 4.82 | 8.04 |
Omit
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 2.98 | 4.54 |
| Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 3.11 | 4.66 | |
| Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Asmol CFC-Free with dose counter | 1 | 5.42 | 5.85 | |
| Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Ventolin CFC-Free with dose counter | 1 | 5.42 | 8.21 |
Insert
| Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Asmol CFC-Free with dose counter | 1 | 5.42 | 5.85 |
| Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Ventolin CFC-Free with dose counter | 1 | 5.42 | 8.21 |
Insert
| Tamoxifen | Tablet 20 mg (as citrate) | Oral | Nolvadex-D | 30 | 4.40 | 8.19 |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.